Navigation

Hyperplasia (benign prostatic) - tadalafil [ID534]

Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia

Status: History
Expected date of issue: TBC
Referral date: July 2012
Process: STA
Notes:

Scoped as part of Batch 23

Topic area:
  • Urogenital
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Grace Jennings
Communications manager: Lyndsey Unwin
Project manager: Rebecca Pye
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 15 October 2012
1st appraisal committee meeting: TBC
Top


 

Consultees and commentators

Consultees

 

Commentators

Manufacturers/sponsors

  • Lilly UK (tadalafil)

Patient/carer groups

  • Prostate Cancer UK

Professional groups

  • British Association of Urological Nurses
  • British Association of Urological Surgeons
  • Royal College of Nursing
  • Royal College of Pathologists

Others

  • Department of Health
  • Welsh Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
  • Medicines and Healthcare Products Regulatory Agency

Comparator manufacturers

  • Actavis UK (tamsulosin)
    confidentiality agreement not signed, not participating)
  • Amdipharm (doxazosin, terazosin)
    (confidentiality agreement not signed, not participating)
  • Apotex UK (tamulosin)
    (confidentiality agreement not signed, not participating)
  • Astellas Pharma (tamsulosin)
  • Boehringer Ingelheim (tamsulosin)
  • Consilient Health (tamulosin)
    (confidentiality agreement not signed, not participating)
  • Discovery Pharmaceuticals (doxazosin)
    (confidentiality agreement not signed, not participating)
  • Focus Pharmaceuticals (tamulosin)
    (confidentiality agreement not signed, not participating)
  • Genus Pharmaceuticals (tamulosin)
    (confidentiality agreement not signed, not participating)
  • GlaxoSmithKline (dutasteride/tamsulosin)
  • Pfizer (doxazosin)
  • ProStrakan (tamsulosin)
    (confidentiality agreement not signed, not participating)
  • Ranbaxy (UK) (doxazosin, tamulosin)
    (confidentiality agreement not signed, not participating)
  • Sandoz (doxazosin, tamulosin)
    (confidentiality agreement not signed, not participating)
  • Sanofi (alfuzosin)
    (confidentiality agreement not signed, not participating)
  • Somex Pharma (tamulosin)
    (confidentiality agreement not signed, not participating)
  • Sovereign Medical (doxazosin)
    (confidentiality agreement not signed, not participating)
  • Teva UK (tamulosin)
    (confidentiality agreement not signed, not participating)
  • Wockhardt UK (tamsulosin)
    (confidentiality agreement not signed, not participating)
  • Zentiva (doxazosin, tamsulosin, terazosin)
    (confidentiality agreement not signed, not participating)

Relevant research groups

  • None

Evidence Review Group

  • Aberdeen HTA Group
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • National Clinical Guideline Centre

Associated public health groups

  • None

Top


 

Project history

Date Update
18 October 2012 The manufacturer of tadalafil has informed NICE that they will not provide an evidence submission for this appraisal. NICE has therefore suspended this appraisal.
Top


 

Key documents

This page was last updated: 15 January 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.